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Heterogeneity  of  antibody-combining  sites  to  homopolysaccharide antigens  can 
readily be demonstrated. With human antidextrans,  specificities  involving a(1  --~ 6)- 
and a(1 --* 2)-, a(1 --* 3)-, a(1 --* 4)-linked Dglucopyranosyl units have been described 
(1-9). In addition it has been shown that antidextrans  of o~(1 --* 6)  specificity pro- 
duced in several individuals differed in their relative affinities  for oligosaccharides of 
the isomaltose series up to isomaltohexaose (IM6) or -heptaose (IMT)  (2, 10, 11 cf. 6, 
12). This is thought to reflect differences in the extents of the complementary areas of 
the antibody-combining sites with the upper limit of complementarity being a chain 
of six or seven a(1  --* 6)-linked glucose units (2, 11 cf, 12). Indeed the antidextran of 
a(1 --* 6) specificity from a given individual has been fractionated into two populations 
that differ in the ease in which they are inhibited by small relative to large oligosac- 
charides of the isomaltose series  (13-16 cf.  12). Similar data have been obtained with 
various mannans (17-19). 
The immunochemistry of levan has not been  as  extensively  studied  (20  cf.  6). 
Levans are homopolymers of Dfructose with predominantly/~(2  -* 6) glycosidic link- 
ages and fl(2 --* 1) branches. Another major class of fructosans is/~(2  -* 1) linked as in 
inulin. Their relatively simple structures thus also lend themselves to immunochemical 
investigations concerning the size and heterogeneity of antibody-combining sites. 
In BALB/c mice immunoglobulin-secreting plasmacytomas can be induced by in- 
traperitoneal injection of mineral oil or implantation of solid plastic material (21, cf. 
22,  23).  A  relatively large number of homogeneous BALB/c myeloma proteins has 
antibody specificity for naturally occurring substances in the environment of inbred 
mouse strains. This has led to the hypothesis (23-25) that plasmacytomas in mice are 
chiefly derived from clones of cells that are stimulated by natural antigens. Since dex- 
trans and levans occur widely in nature and microorganisms producing dextran and 
levan are present in the gastrointestinal tract (26),  it is not surprising that myeloma 
proteins have been found that react specifically  with these polysaccharides (27-29). 
Myeloma proteins with antibody activity have shown ligand binding characteristic 
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of homogeneous combining sites (30-34) while the antibody response to immunization 
with polysaccharides is  generally heterogeneous,  frequently yielding  a  spectrum  of 
antibodies with combining sites  varying in their complementary areas  (cf.  12). How- 
ever, if one were to study a number of myeloma proteins reactive with a given antigen, 
it could be anticipated  that the individual myeloma-produeing clones might differ  in 
the specificity and site size of their secreted immunoglobulin since each clone is pre- 
sumably selected from a heterogeneous cell population by a random malignant trans- 
formation. 
The present  report  is  a  study of eight mouse myeloma proteins,  four with 
antidextran  and  four with  antifructosan  specificity,  and  of human  antilevan 
produced by immunization of two individuals with levan. The data clearly show 
that  combining  sites  of  individual  mouse  myeloma  proteins  reactive  with 
dextran can differ from one another in specificity, size, and extent of their com- 
plementary areas. They also indicate that the antifructosan-specific myelomas 
fall into two classes with/5(2 -+ 6) or/3(2 --* 1) specificity and that, in the latter 
class,  individual  proteins differ in the sizes and extents  of the complementary 
areas of their combining sites. This is consistent  with  the hypothesis that  each 
myeloma protein represents a  population of molecules with homogeneous com- 
bining sites produced by a clone selected at random from the diverse population 
of cells that usually give rise to heterogeneous populations of antibody mole- 
cules after antigenic stimulation. 
Materials ana Methods 
Myeloma Proteins.--Myeloma  proteins were produced in BALB/c mice, screened for anti- 
body activity, and typed at the National Institutes of Health or the Salk Institute (Table I). 
Protein  W3129 was purified on a Sephadex (3-75 column (Pharmacia  Fine  Chemicals, Inc., 
Piscataway, N. J.) and supplied by Dr. N[artin Weigert of the Salk Institute, San Diego, Calif. 
Human Antilevans.--Two  human antilevan  sera were studied.  Antilevan  from subject  1 
(l Da3L24 +  Ds4L25) (20) had been previously absorbed with insoluble blood group substance 
(35) and with Sephadex (13) to remove anti-A antibodies and antidextrans,  respectively. Anti- 
levan  C.S. was prepared  by immunization with levan P6  (20) and was kindly  supplied by 
Doctors Valee Harisdangkul  and Charles L. Christian,  Cornell University  Medical College, 
New York. 
TABLE I 
Myeloma Proteins Reactive with Dextran or Fructosans 
Myeloma protein  Reacts with  Type  Present  in  Origin 
W3129  Dextran  IgAg  Serum  Salk 
W3434  Dextran  IgAx  Serum  Salk 
QUPC 52  Dextran  IgA  Ascitic fluid  NIH 
UPC 102  Dextran  IgAX  Ascitic fluid  NIH 
W3082  Fructosan  IgAK  Serum  Salk 
UPC 61  Fructosan  IgA  Ascitic fluid  NIH 
Y5475  Fructosan  IgAt¢  Serum  Salk 
UPC 10  Fructosan  IgG2a  Ascitic fluid  NIH J. CISAR~  ]~. A.  KABAT~  3"  LIAO~  AND  ~[. POTTER  161 
Antigens.--The dextrans and levans used in this study have been described previously (20, 
36 el. 6). The proportions of a(1 ~  6), a(1 ~  3)-like, and a(1 --+ 4)-like linkages in the dex- 
trans used are given in Fig. 2. Inulin was from Nutritional Biochemicals Corp.,  Cleveland, 
Ohio. 
Motto- and OUgosaccharides.--Glucose, fructose, sucrose,  isomaltose (IM2), isomaltotriose 
(IM3),  isomaltotetraose  (IM4),  isomaltopentaose  (IM5),  isomaltohexaose (IM6),  isomalto- 
heptaose  (IM7),  maltose, kojibiose, methyl aDglucopyranoside,  methyl 8nglucopyranoside, 
methyl otDmannopyranoside,  methyl 3-O-methylomglucopyranoside, turanose (3-O-o~Dglucosyl- 
Dfructose),  and the branched oligosaccharides 3SaDglucosylisomaltotetraose, 34aDglucosyliso - 
maltohexaose, and 44ozDglucosylisomaltohexaose 1 were those previously described  (4,  8,  13, 
36-38).  otDGlc(1 -+ 6)DGlcNA¢  (6-O-aDglucosyl-N-acetylDglucosamine)  was  from  Dr. A. L. 
Tarentino, Division of Laboratories and Research, New York State Dept. of Health, Albany, 
N. Y. (39).  The a(1 --~ 3)-linked series of glucose oligosa¢charides (nigerodextrins) were pro- 
vided by Dr. I. R. Johnston, University College, London, England (40). The di-, tri-, and tet- 
rasaccharides,  8Dfructofuranosyl(2  --*  6)Dglucopyranose  (1F1G),  8Dfructofuranosyl(2  --* 
1)SDfructofuranosyl(2  ~  6)Dglucopyranose  (2F1G), and 8Dfructofuranosyl(2 --* 1)SDfructo- 
furanosyl(2 --* 1)SDfructofuranosyl(2 ~  6)Dglucopyranose  (3F1G), were obtained from Dr. F. 
Arcamone, Instituto Richerche Farmitalia, Milano, Italy (41).  The preparation of their cor- 
responding  alditols has  been described (29).  Levanbiose  (6-o-SDfructosylDfructose)  and  a 
branched levantriose, 8Dfructofuranosyl(2 --* 1)LSDfructofuranosyl(2  --* 6)]Dfructose,  in which 
the fructose units were joined by one 8(2 --* 1) and one 8(2 --* 6) linkage, were kindly sup- 
plied by Dr. S. T. Bauer, The Hebrew University, Jerusalem, Israel. 
Immunochemical  Methods.--Quantitative  precipitin  and  inhibition  assays  were done  by 
a microprecipitin technique (6) using 3-8 #g of protein N per determination. Total N  in the 
washed precipitates was measured by the ninhydrin method (42). The solubility of precipitates 
was determined as previously described (6, 29). 
Protein W3129 (2.9 mg of N in 0.6 ml) was separated into monomer- and polymer-rich frac- 
tions by filtration at 4°C through an 80 X  1.5 cm Bio-Gel 1)-300 (100-200 mesh) column (Bio- 
Rad  Laboratories,  Richmond,  Calif.)  equilibrated  with  0.01  M  phosphate-buffered  saline 
(1)BS), pH 7.4 (Fig. 1). The contents of tubes 27-31 and 35-40 were pooled to give polymer and 
monomer fractions, respectively. A Spinco model E  analytical ultracentrifuge equipped with 
ultraviolet  optics  and  automatic  temperature  control was  used  for sedimentation  velocity 
measurements. Analysis of sedimentation patterns at the 25, 50, and 75% levels of ultraviolet 
absorbance gave s2o.w values of 7.7S, 6.9S, and 6.1S with the monomer fraction (70/zg N/ml) 
and 26S,  17.7S, and 13.1S with the polymer fraction (108 #g N/ml). The material in the po- 
lymer fraction sedimenting at 26S or faster (25% of the protein) apparently resulted from ag- 
gregation since only 12 and 25% of unfractionated W3129 sedimented at or faster than 18.1S 
and  14.6S,  respectively. With the polymer fraction, 90/0 of the protein was 9.8S  or smaller 
1 The structures of the branched oligosaccharides may be represented as follows: G, Dglu- 
copyranosyl; Gr, reducing Dglucose; --% a(1 --+ 6) link; T, a(1 --* 3) link; $, a(1 --* 4) link. 
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FIG. 1.  Separation of myeloma protein W3129 into polymer-rich (tubes 27-31) and mo- 
nomer-rich (tubes 35-40) fractions by chromatography  on Bio-Gel  P-300. 
while 8% of the monomer  fraction was 9.2S or larger. Immunoadsorption  experiments  using 3 
mg Sephadex G-75 were done with approximately 10/.¢g  of myeloma N in a total volume of 
250 #1. The percentage of myeloma protein N adsorbed to the Sephadex or precipitated by 
dextrans was determined by analyses of supernatants. 
RESULTS 
Quantitative Precipitin  Studies  with  Mouse  Myeloma  Proteins  Reactive with 
Dextran.--Initial screening  of myeloma proteins W3434,  W3129,  QUPC  52, 
and UPC 102 with several antigens revealed specificity for dextrans. To estab- 
lish the pattern of reactions for each myeloma protein, quantitative precipitin 
assays were performed with dextrans differing in their proportions of a(1 ~  6), 
a(1 --~ 4)-like, and a(1 --~ 3)-like glycosidic linkages. 
Myeloma proteins W3434 and W3129 reacted similarly with  the dextrans 
tested (Fig. 2 A  and B, respectively). Both were precipitated most efficiently 
by native dextrans high in a(1 --~ 6)  glycosidic linkages  (B512 or N236  and 
]]1141) or by those high in a(1 ~  6) and a(1 ~  4)-like linkages that are largely 
a(1 --~ 2)  (B1399, B1299-S-3, and B1424) and 50% precipitation required ap- 
proximately 4  #g of these dextrans; B1399 precipitated about  2  #g more N 
from W3434 than did any of the other dextrans. Larger quantities of dextrans 
high in a(1 --~ 3)-like linkages (B1498S, B1355-S-4, and B1501S) were required 
for 50%  precipitation,  11  #g  with W3434,  and  8  #g  with W3129.  Dextran 
B742L-R with 81% a(1 ~  6) linkages did not react like the other dextrans with 
high a(1 --~ 6) contents and approximately 8 #g were required for 50% precipi- 
tation of protein W3129; similar results were obtained with a  pool of W3434 
serum other than that used for Fig. 2 A : the atypical behavior of this dextran 
has been repeatedly shown (3 cf. 6). LINKAGES  LINKAGES  LINKAGES 
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FIG. 2.  Quantitative precipitin curves of mouse myeloma proteins with various dextrans. 
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Limited data with myeloma protein QUPC 52 indicated a pattern of precipi- 
tin reactions that differed from that of W3434 or W3129 (Fig. 2 C). Dextrans 
B512 and B1255 with 96 and 86% a(1 --> 6) linkages, respectively, reacted well 
and approximately 5/zg gave 50% precipitation. Dextrans B1399 and B1498S 
with 65  and 62% a(1 ~  6)  linkages reacted intermediately, while B1299-S-3 
and B1355-S-4  with 50 and 57 % a(1 ~  6) linkages reacted poorly. As noted 
for W3434 and W3129,  dextran B742L-R reacted less well with QUPC 52 than 
did the other a(1 -+ 6)-linked dextrans. 
Mouse myeloma protein UPC  102 differed from the three previous antidex- 
tran myelomas and precipitated best with those dextrans containing high pro- 
portions of a(1 --+ 3)-like glycosidic linkages (B1498S, B1355-S-4, and B1501S) 
(Fig. 2 D). Dextrans B742C-3R and Bl141 were exceptional and although they 
contained 21  and 18%, respectively, of a(1 ~  3)-like linkages, they precipi- 
tated only a portion of the total UPC 102 N. Those dextrans with low a(1 --* 3)- 
like and high a(1 --~ 6) and/or a(1 ~  4)-like linkages reacted poorly. 
With a(1 ~  6)-specific  human antidextrans, clinical dextran N-150N  (mol 
wt 60,000)  (43)  precipitated 15 % less  N  than did native dextran B512  (mol 
wt 107-108) (cf. 6); however, N-150N precipitated 50, 75, and 85 % less N than 
did B512  with myelorna proteins W3129,  W3434,  and QUPC 52, respectively, 
(Fig. 2).  Solubilities of precipitates of protein W3129 with N-150N and B512 
were similar (0.8 and 1.0 #g N/ml, respectively) and indicated that the failure 
of dextran N-150N  to precipitate all of the myeloma protein did not reflect a 
high solubility of the specific precipitates. 
Since lgA myeloma proteins consist of monomeric and polymeric molecules 
and isolated monomer fractions, although capable of antigen binding have been 
found not to precipitate (30, 44),  the influence of monomeric IgA on precipitin 
curves obtained with dextrans B512  and N-150N  was investigated. Purified 
W3129 and the previously described monomer- and polymer-rich fractions of 
this myeloma protein were equally reactive with dextran since 85-90 % of each 
could be adsorbed on to Sephadex G-75.  Quantitative precipitin curves with 
dextrans B512  and N-150N  are shown in Fig. 3.  Unfractionated W3129 was 
64%  precipitable with dextran B512  and 24%  precipitable with dextran N- 
150N. The polymer fraction of W3129 was 88 % precipitable with B512 and 54 % 
precipitable with N-150N.  The monomer fraction was 45 and 5 % precipitable 
with B512 and N-150N, respectively. Thus the percentage of N-150N to BS12- 
precipitable N  was 40% with unfractionated W3129,  60% with the polymer- 
rich fraction, and 10 % with the monomer-rich fraction of W3129. 
Quantitative Inhibition  Assays of Myeloma Proteins Reactive with Dextrans.-- 
The abilities of various oligosaccharides to inhibit precipitation between pro- 
teins W3434  or W3129  and dextran  B512  were  assayed.  Both proteins  dis- 
played specificity for a(1 ~  6)-linked glycosyl residues since kojibiose, nigerose, 
and maltose were poorer inhibitors on a molar basis than methyl aDglucoside, 
which in turn was less effective than IM2 (Fig. 4 A  and B). With W3434 the J.  CISAR,  E.  A.  KABAT~ J.  LIAO~ AND  M.  POTTER  165 
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FIG. 3.  Quantitative  precipitin  curves  of protein  W3129 (A)  and  its  polymer-  (B)  and 
monomer-rich  (C) fractions  (cf. Fig.  1) with: D, native dextran  B512; X, clinical dextran, 
N-150N. 
isomaltose  oligosaccharides inhibited  in  the  following order:  IM7  =  IM6  = 
IM5  >  IM4 >  IM3 >> IM2  (Fig. 4 A). The order of inhibition with protein 
W3129 was: IM7 =  IM6 =  IM5 >  IM4 =  IM3 >> IM2 (Fig. 4 B). Thus both 
proteins  showed  complementarity  to  a  terminal  nonreducing  chain  of  five 
glycosyl residues in a(1 --~ 6) linkage. However, W3129 and W3434 differed in 
their  relative  affinities  for IM4,  W3129  showing no  additional  inhibition  by 
IM4 over IM3 on a molar basis. 
Additional data with W3129 indicated that a(1 ~  6)-linked oligosaccharides 
containing a single glucose branch on carbon 3 or 4 of different glucosyl residues GLUCOSE 
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FIG. 4.  Inhibition by various oligosaccharides of precipitation of mouse myeloma proteins 
by dextran. 
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were poorer inhibitors than the corresponding a(1 --~ 6)-linked oligosaccharides. 
Thus  34aDglucosylisomaltohexaose  and  44aDglucosylisomaltohexaose  were 
slightly less inhibitory than IM6 and were similar to IM3 or IM4, while 33aD  - 
glucosylisomaltotetraose was  a  poorer inhibitor on  a  molar basis  than  IM4 
(Fig. 4 B). The importance of the second glucose residue from the nonreducing 
end was also shown by finding that aDGlc(1 ---> 6)DGlcNAc  was  less  potent 
than IM2.  Methyl  aDglucoside  was  a  much  better  inhibitor  than  methyl 
~Dglucoside  and  methyl aDmannoside  indicating,  respectively,  that  the  a- 
glycosidic linkage and the equatorial position of the hydroxyl group on the 
second carbon  of the  terminal nonreducing glucose residue were  critical for 
complementarity. Methyl 3-O-methylaDglucoside and methyl aDglucoside were 
equally potent. 
Precipitation of myeloma protein QUPC 52 with dextran B512 was effectively 
inhibited by the isomaltose series of oligosaccharides and the order of inhibition 
was: IM7  =  IM6 >  IM5 >  IM4 >> IM3 >> IM2 (Fig. 4 D). Since IM7 and 
IM6 were both twice as inhibitory as IM5, the combining region of QUPC 52 
clearly showed complementarity to a terminal chain of six glucosyl residues in 
a(1  ~  6)  linkage and was  thus larger  than  those  of  proteins  W3434  and 
W3129. 
With myeloma protein UPC 102 nigerose was a better inhibitor than maltose, 
kojibiose, or  isomaltose  (Fig. 4 E).  Methyl aDglucoside, methyl 3-O-methyl- 
anglucoside, and glucose were equally inhibitory and were more effective on a 
molar basis  than methyl/~I)glucoside and methyl aDmannoside. Assays with 
the nigerose series of oligosaccharides showed nigerotriose, -tetraose, -pentaose, 
and  -hexa-heptaose  to  be  equal  on  a  molar  basis  and more  effective than 
nigerose  or  the  branched  oligosaccharides  34aDglucosylisomaltohexaose and 
44aDglucosylisomaltohexaose. Thus the combining site of UPC  102  was most 
complementary to nigerotriose. 
With protein W3129 the relative inhibitory powers of the isomaltose oligo- 
:saccharides were approximately the same as judged by their abilities to com- 
pete with determinants on native dextran B512  or clinical dextran N-150N. 
However, the shapes of inhibition curves obtained with B512  (Fig. 4 B) were 
:strikingly different from those with N-150 N  (Fig. 4 C). With B512,  a biphasic 
curve was obtained in that the initial 40% of inhibition required relatively low 
oligosaccharide concentrations compared with those needed to inhibit the re- 
maining 60 %. This biphasic character was not observed in the N-150N system 
in  which  inhibition  curves  resembled  those  usually found with  antibodies. 
Inhibition curves with purified W3129 and B512  were also biphasic and indi- 
cated that 20-30% of the precipitable myeloma N was easily inhibited by IM6 
or IM3 (Fig. 5 A). Studies with W3129 polymer- and monomer-rich fractions 
(Fig.  5  B  and  C,  respectively)  resolved the biphasic  inhibition curve into 
typical quantitative precipitin  curves and indicated that the biphasic curves 
were  attributable  to  the  preferential  inhibition  of  W3129  monomers  ove  r 
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Fzo. 5.  Inhibition  by oligosaccharides of predpitation of protein W3129 (A) and its polymer 
(B) and monomer-rich (C) fractions (cf. Fig. 1) by dextran. A, isomaltotriose; O, isomalto- 
hexaose. 
Quantitative  Precipitin  Studies with Mouse Myeloma Proteins  Reactive witk 
Fructosans.--Proteins  UPC  61  and  W3082  reacted  similarly  with  various 
levans and with inulin (Fig. 6 A and B). Approximately 1.5/zg of Hestrin levan 
A or Hestrin levan B and 3--4/~g of Hestrin native levan, levan P6, and levar~ 13  HESTRIN  LEVAN  A  O  LEVAN  P6  A  LEMAN  B  523  FR. M 
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F~G. 6.  QuantitatEve precipitin curves of mouse myeloma proteins with various leva~s and 
with inulin. 
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B 523 fraction (Fr.) M gave 50 % precipitation of either protein. Larger amounts 
of levans B512, PP2 Fr. B, and B512 Fr. E were required for 50% precipitation. 
The/3(2 --+ 1)-linked fructosan, inulin,  reacted very well with both proteins, 
and 2 #g precipitated approximately 70 %  of the UPC 61  N  and 50 % of the 
W3082  N.  By  contrast,  perennial  rye  grass  levan,  which  is  predominantly 
/3(2 --~ 6)-linked (45, 46), reacted hardly at all. 
Precipitin reactions with myeloma  proteins Y5476 and UPC 10 (Fig. 6 C and 
D) differed in two basic respects from those described for UPC 61 and W3082. 
When the antifructosan myeloma proteins were adjusted to the same amount 
of precipitable N, the quantities of each levan required for 50 % precipitation of 
Y5476 and UPC  10 were roughly one-half to one-quarter those with UPC 61 
and W3082.  Secondly, Y5476 and UPC  10 did not react with inulin but were 
precipitated by perennial rye grass levan. The precipitin reactions of Y5476, an 
IgA protein, and UPC  10, an IgG, were not identical; however, both proteins 
reacted well with levan P6 and  the Hestrin levans while greater amounts of 
B512  PP2  Fr. B  and B512 Fr.  E  were required for 50% precipitation; B523 
Fr. M  was intermediate. 
Oligosaccharide Inhibition  Studies with Antifructosan  Mouse Myeloma _Pro- 
teins.--Inhibition studies with UPC 61 and W3082 (Fig. 7 A  and B) indicated 
that  their specificities were very similar.  Both were inhibited by/3(2 --*  1)- 
linked fructose oligosaccharides And 3F1G was  the best inhibitor with about 
1.8  nM giving 50% inhibition. When 3F1G was reduced to its  corresponding 
alditol, its inhibitory power decreased to  that of 2F1G;  both  3F1G  reduced 
and 2F1G were approximately 60% as effective as 3F1G. Reduction of 2F1G 
to its alditol resulted in a fivefold decrease of inhibitory power for UPC 61 and a 
ninefold decrease with W3082.  With both proteins the branched levantriose, 
containing a/3(2 --~ 1)- and a/3(2 --~ 6)-linked terminal fructofuranosyl residue, 
was somewhat more effective than  2F1G reduced. Levanbiose, the/3(2 -~ 6)- 
linked  disaccharide,  was  approximately 1/~  5  as  inhibitory  as  2F1G  reduced 
but four to five times more effective than sucrose and  1F1G, which were simi- 
lar. Turanose, fructose, and glucose were very poor inhibitors of precipitation. 
Mouse myeloma proteins UPC  10 and Y5476 were not inhibited by any of 
the  oligosaccharides assayed  (Fig.  7 A  and  B  symbols with  asterisks).  The 
highest amounts tested were greater than those required for 50 % inhibition of 
W3082  or UPC  61  by factors from  100  to  1,000  with 3F1G,  10  to  60 with 
branched levantriose, 4 to 10 with levanbiose, 1 to 7 with  1F1G, 40 to 100 with 
sucrose, and 0.5  to 3 with turanose. Fructose in amounts greater than 105 nM 
appeared to inhibit both myeloma proteins; however, under these conditions 
the sugar concentrations were between 10 and 20 % and increased viscosity may 
have affected the quantitative inhibition assays. 
Quantitative  Precipitin  and Oligosaccharide Inhibition  Studies with ttuman 
A ntilevans.--Levan P6 precipitated 2.5/zg of N from 0.5 ml of human antilevan 
C.S. and 50 % precipitation required 1.5/zg of levan. Perennial rye grass levan ]'.  CISAR,  E.  A.  KABAT,  J.  LIAO~  AND  M.  POTTER  171 
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FZC. 7. Inhibition by various oligosaccharides  of precipitation of mouse  myeloma  proteins 
and human antilevans by levan. 
and inulin in amounts up to 9/zg did not precipitate with antilevan C.S. Quan- 
titative precipitin  reactions with various fructosans and the antilevan from 
subject 1 DnL2 have been reported previously (20); with 1.5 ml of 1 D,3144 + 
1 D8~I45 serum,  taken 9 yr later,  levan P6  precipitated 6/zg of antilevan N 
with 1/~g of !evan PG, giving 50% precipitation.  Small amounts (1-5/zg)  of 
perennial rye grass levan precipitated 0.5/zg of N  while inulin failed to pre7 
cipitate. With both antilevans, precipitation by levan P6 was effectively in- 
hibited with excess  perennial rye grass levan  (mol wt approximately 5,000) 
(45) and 160 #g gave 40-50% inhibition. Increased inhibition could not be ob- 
served as greater amounts of perennial rye grass levan precipitated a  serum 
protein that apparently was distinct from antilevan, as had previously been 172  IMMUNOCItEMICAL  STUDIES  ON  MYELOMA  PROTEINS 
noted with inulin for  the  earlier sample  (20).  With  both  anfilevans, inulir~ 
(tool wt approximately 5,000) was completely inactive as an inhibitor in amounts 
up  to  360  #g.  Thus like myeloma proteins  UPC  10 and Y5476,  the human 
antilevans were reactive with determinants on perennial rye grass levan but not 
on inulin. Nor were the antilevans inhibited significantly by the oligosaccha- 
rides  that  were  active  with myeloma proteins  W3082  and  UPC  61  (Fig.  7 
symbols with crosses). 
DISCUSSION 
The findings presented on myeloma proteins reactive with dextrans and those 
reacting with the fructosans levan and inulin provide a crucial link in the chain 
of evidence relating specificity of myeloma proteins with antibody specificity. 
The mouse myeloma proteins QUPC 52, W3434,  and W3129 reacted with the 
isomaltose oligosaccharides in  a  manner  remarkably similar  to  that  of  the 
a(1 ~  5)-specific human antidextrans. Earlier studies with human antidextrans 
established the upper limit for an antidextran-combining site as complementary 
to a  terminal chain of six or seven a(1 ~  5)-linked glucose units (10,  11 cf. 6, 
12). Inhibition assays with isomaltose oligosaccharides showed the antidextran 
produced by a  given individual to be heterogeneous in that molecules varied 
in the sizes of their combining sites (2 cf. 12). Further studies showed that the 
antidextrans from a given individual could be fractionated into two populations 
with combining sites of different sizes (13-15). The present studies on myeloma 
proteins  reactive with  dextrans have  clearly shown  that these proteins  also 
have combining sites of different sizes, one having a site complementary to six 
glucoses, two others to five glucoses,  and one to three glucoses.  The following 
paper by Weigert et al. (47) clearly establishes that isomaltopentaose, the oligo- 
saccharide which best satisfies the combining site of a myeloma protein specific 
for dextran, is also the best inhibitor of its idiotypic specificity. Thus, idiotypic 
specificity is  clearly seen  to  be  progressively affected by a  conformational 
change, involving each residue of the determinant that interacts with its specific 
combining site. Moreover myeloma proteins reactive with dextran differ in their 
idiotypic specificities if they differ in the sizes of their combining sites (QUPC 
52 vs. W3434 or W3129) and even if the sizes of their combining sites are similar 
but  the  relative  contribution  of  each  residue  to  the  binding  energy varies 
(W3434 and W3129). Also UPC 102, an IgA protein, and MOPC 104E,  an IgM 
protein  (27)  whose precipitation  was  inhibited best  by an a(1  --~  3)-linked 
trisaccharide, nigerotriose, both inhibited the  .[558 idiotype reaction  equally 
but were much less effective than J558 itself, which was shown (29) to be most 
complementary to an a(1  ~  3)-linked pentasaccharide. With both UPC  102 
and ]558, maltose was a better inhibitor than isomaltose; however, with MOPC 
104E, the reverse was noted. 
With myeloma proteins reactive with fructosans, two W3082  and, UPC 51, 
both of which react with inulin and are inhibited best  by the tetrasaccharide J. CISAR,  E. A.  KABAT,  ~[. LIAO,  AND  M.  POTTER  173 
3F1G, are identical in idiotypic specificity and differ in  idiotype from  J606, 
which also reacted with inulin but was most complementary to trisaccharide 
2F1G  (29).  The  other  two  fructosan-specific proteins  UPC  10  and  Y5476, 
which  like human antilevans appear  to  have /3(2 --~  6)  specificity, differ in 
idiotype from W3082. 
The detailed data given above for myeloma proteins reactive with dextran or 
with fructosans favor a high degree of similarity for these sites and antibody- 
combining sites. Thus the concentrations of isomaltose oligosaccharides required 
for inhibition of precipitation of the myeloma proteins by dextran were in the 
same range as those previously reported for human antidextran of a(1 --~ 6) 
specificity (2, 8, 9, 13, 15, 16, 48 cf. 6). Also, the dextrans used for quantitative 
precipitin  curves  behaved  in  a  quite  comparable  manner  with  the  mouse 
myeloma proteins as with human antidextrans. It is highly significant that the 
two dextrans found to react differently with human a(1  --* 6)  antidextrans, 
with Type II horse and rabbit antipneumococcal antibody, and with Type XX 
antipneumococcal antibody (3, 36  cf. 6)  showed the identical anomalous be- 
havior with two of the a(1 -~ 6)-specific myeloma proteins (W3129 and W3434) 
studied.  Thus,  more  dextran  B742L-R  was  required  for  precipitation  than 
expected from its content of a(1 --*  6)  linkages, while B1299-S-3  was much 
more  effective in precipitating than expected from its content of a(1  --+ 6) 
linkages. Protein QUPC 52 with the largest size site reacted poorly with both 
B1299-S-3  and B742L-R, indicating its high specificity for long linear chains. 
These quantitative findings, in addition to the lower potencies of a(1  ~  4)-, 
a(1 --~ 3)-, and a(1 --~ 2)-linked disaccharides, provide important evidence that 
the isomaltose oligosaccharides are the actual determinants for which the sites 
on the myeloma proteins are specific. 
The specificity of W3129 was examined in greater detail than those of the 
other two myeloma proteins. The only structural deviation from the isomaltose 
series that was tolerated was the substitution of a methoxyl group on C-3 of 
methyl  aDglucoside,  which  did  not  reduce  complementarity.  That  methyl 
aDmannoside and methyl ~Dglucoside  were  less  inhibitory than methyl a~ 
giucoside and that aDGlc(1  --~ 6)DGlcNAc,  although a  better  inhibitor  than 
methyl aDglucoside, was less potent than IM2 indicated that the W3129  site 
required a  terminal isomaltose determinant. The findings with the isomaltose 
oligosaccharides containing a single glucosyl branch at the second or third resi- 
due from their nonreducing ends are strikingly similar to those with a(1 --* 6)- 
specific human antidextrans (8) in that branching inhibited sterically to some 
extent but did not prevent access to the W3129-combining region. 
It is well known that the immunodominant  group, which in polysaccharides is 
often the terminal nonreducing end, contributes most to the binding energy 
with each successive residue of the determinant contributing a  smaller incre- 
ment (cf. 6,  12). Thus with human antidextran, assuming a AF  ° for the hexa- 
saccharide  of  --7,500  cal.,  the  first  five  sugars  from  the  nonreducing  end 174  IMMUNOCHEMICAL  STUDIES  ON  MYELOMA  PROTEINS 
contributed 97 and 98 %, the first four 91 and 95 %, and the first three 75 and 
90%  (2);  with myeloma protein  QUPC  52,  most complementary to  six  glu- 
coses,  the values for the first five, four, and three were 93, 88, and 74 % while 
with the two complementary to five glucoses (W3129  and W3434)  the corre- 
sponding values for four, three, and two glucoses were 95  and 98%,  95  and 
94%,  and  75  and  74%,  respectively.  Since  the  antibodies were mixtures  of 
molecules with different-sized combining sites, the values are in good agreement. 
Thus the relative binding energies of the homogeneous myeloma proteins are 
quite comparable to those for the heterogeneous antibodies.  Using a value of 
--6,400 cal. for AF  ° (16), changes from the above percentages were not signifi- 
cant. 
Myeloma proteins specific for fructosans were of two types as distinguished by 
their reactivity with inulin. Those precipitated by inulin (W3082 and UPC 61) 
appeared most specific for/3(2 ---> 1)-linked fructose oligosaccharides since the 
disaccharide levanbiose, the only member of the/3(2 --~ 6)-linked series  avail- 
able, was a much poorer inhibitor than 2F1G reduced and only slightly better 
than  sucrose and  1F1G.  In  addition, with both proteins,  maximum comple- 
mentarity was  for  three  /3(2 --~  1)-linked  fructose units plus  an  additional 
/3-linkage (3F1G). W3082  and UPC 61 appear to have virtually identical spec- 
ificities but differ from myeloma protein J606 (29) in the size of their combining 
regions as measured with 13(2 --~ 1)-linked oligosaccharides and in their approxi- 
mately 20-fold greater  affinity for  sucrose  and for  1F1G  than  for  turanose 
(3-O-aDglucosylDfructose),  while  with  J606,  turanose  was  about  twice  as 
potent as sucrose and 1F1G. 
UPC 10 and Y5476 as well as the human antilevans did not react with inulin 
nor were they inhibited by any oligosaccharides available; thus their specifici- 
ties could not be studied. It is likely that these myeloma proteins and the human 
antilevans have/3(2 --~ 6) specificities as they reacted well with the fl(2 --~ 6)- 
linked perennial rye grass levan (45, 46).  Previous findings with the antilevan 
from subject 1 also suggested a/3(2 --~ 6) specificity (20). 
The possibility for two types of fructosan-specific combining sites is com- 
patible with models of fl(2 --~ 6)- and fl(2 --* 1)-linked fructosyl trisaccharides. 
Thus the terminal nonreducing f~(2  --*  1)- and/3(2--* 6)-linked fructofuranosyl 
residues  appear  to  be  very similar while chains of/3(2  -~  6)  and/3(2  --~  1) 
residues are quite different (Fig. 8). This could account for the/3(2 --~ 1) spec- 
ificity of those proteins  reactive with inulin and suggests that their reactions 
with levans occur at the nonreducing ends of/5(2 --~ 6) chains. Those proteins 
reactive with levans but  not with inulin would probably have sites comple- 
mentary to chains of ~(2 --~ 6)-linked fructoses longer than two sugars since 
inhibition could not be obtained with fairly high amounts of levanbiose or of 
branched levantriose. 
With IgA myeloma protein W3129, the differences from the classical behavior 
in quantitative precipitin  (Fig. 3 A)  and inhibition assays  (Fig. 5)  were ac- 
counted for by the  presence  of a  monomer-polymer system. The ability of J.  CISAR,  E.  A.  KABAT.  J.  LIAO~ AND  M.  POTTER  175 
FIG. 8.  Models of trisaccharides of fructose. Left:/~Dfructofuranosyl(2 ---+  1)/~Dfructofurano- 
syl(2 -+ 1)Dfructose. Right: ~Dfructofuranosyl(2 --+ 6)/~Dfructofuranosyl(2 ---+  6)Dfructose. The 
reducing end has a square of black tape on the hydrogen of the glycosidic hydroxyl. 
W3129 monomer to inhibit competitively precipitation by polymer was much 
greater with clinical dextran N-150N (Fig. 3 C) than with native dextran B512 
(Fig. 3 B). Residual precipitation by the monomer fraction was most likely due 
to  small  amounts  of  polymer  present.  Thus,  inhibition  of  precipitation  of 
polymer by monomer rather than  combining site heterogeneity or solubility 
was the primary basis for the two dextrans precipitating different amounts of 
N  from W3129. This finding strongly supports the explanation suggested (49) 
to  account  for  the  failure of  a  soluble  antigen  to  precipitate  as  much  of a 
myeloma protein as could be removed on an insoluble adsorbent prepared from 
the same antigen and to account for differences in amounts of myeloma protein 
precipitated by various antigens. Moreover, since dextrans N-150N and B512 
differ only in molecular weight, it appears that IgA monomer acts more effec- 
tively as an inhibitor with an antigen having fewer determinants per molecule. 
Indeed with the IgA myeloma proteins J558  (29)  and UPC  102,  which were 
specific for nigerose oligosaccharides,  more myeloma protein N  was  precipi- 176  IMMUNOCHEMICAL STUDIES ON  MYELOMA PROTEINS 
tated by dextrans higher in a(1 --~ 3)-like linkages and therefore containing 
more determinants per molecule. 
SUMMARY 
Four BALB/c IgA  mouse myeloma proteins  (W3129,  W3434,  QUPC  52, 
and  UPC  102) reactive with  dextran,  four myeloma proteins  reactive  with 
fructosans, three IgA (W3082, UPC 61, and Y5476),  and one IgG2a (UPC 10), 
and two human antilevans were studied immunochemically. Quantitative pre- 
cipitin and inhibition assays showed that W3129, W3434, and QUPC 52  had 
specificities for isomaltose oligosaccharides similar to  those previously found 
with a(1 --~ 6)-specific human antidextrans. W3129 and W3434 were most com- 
plementary  to  IM5  but  W3129  reacted  equally with  IM4  and  IM3  while 
W3434 had a greater affinity for IM4 than IM3. QUPC 52 had a larger com- 
bining region and was most complementary to IM6. Protein UPC  102  (IgA), 
like MOPC 104E  (IgM) (27), was most complementary to the a(1 --+ 3)-linked 
trisaccharide,  nigerotriose, and  thus differed from J558  (29),  which  was  in- 
hibited best by nigeropentaose. UPC 102 was similar to J558 but they differed 
from MOPC 104E in their reactions with non-a(1 --~ 3)-linked disaccharides. 
The fructosan-specific myeloma proteins fell into two groups with different 
specificities. The first group, W3082  (IgA), UPC 61  (IgA), and the previously 
studied J606  (IgG3)  (28, 29), reacted with inulin and W3082  and UPC 61 ap- 
peared  to  have  identical  specificities  for  fl(2  --*  1)-linked  fructofuranosyl 
residues  with  maximum  complementarity for  the  tetrasaccharide  /3Dfructo- 
furanosyl (2 --~  1)/3Dfructofuranosyl(2  --~ 1)/~Dfructofuranosyl(2  --~ 6)Dglucose 
while protein J606 was inhibited best by the trisaccharide/~Dfructofuranosyl- 
(2 --~  1)/3Dfructofuranosyl(2  --~ 6)Dglucose.  W3082  and UPC  61  also differed 
from J606 in their behavior toward sucrose and flDfructofuranosyl(2 --~ 6)D- 
glucose as compared with aDglucosyl(1 --~ 3)Dfructose (turanose). The second 
group containing myeloma proteins UPC 10 (IgG2a) and Y5476  (IgA) behaved 
similarly to human antilevans in that neither reacted with inulin nor were they 
inhibited by the fi(2 --+ 1)-linked fructose oligosaccharides. Unlike the/~(2 --~ 1)- 
specific  proteins,  they reacted with perennial rye grass levan that contained 
over 90%  /3(2 --~  6)links.  The differences in specificity and site size  among 
homogeneous mouse myeloma proteins reactive with the same antigenic deter- 
minant are completely consistent with the concept that they represent products 
of homogeneous clones selected from the known heterogeneous population of 
antibody-forming cells. 
We kindly thank  Doctors Melvin Cohn and Martin Weigert of the Salk  Institute, San 
Diego, Calif. for supplying materials and for their cooperation during these studies. 
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